These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 17852016)

  • 21. Design of clinical therapeutic trials in amyotrophic lateral sclerosis.
    Brooks BR; Sufit RL; DePaul R; Tan YD; Sanjak M; Robbins J
    Adv Neurol; 1991; 56():521-46. PubMed ID: 1853781
    [No Abstract]   [Full Text] [Related]  

  • 22. ALS trial design: expectation and reality.
    Miller RG; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():52-4. PubMed ID: 15512873
    [No Abstract]   [Full Text] [Related]  

  • 23. A sequential procedure for monitoring clinical trials against historical controls.
    Xiong X; Tan M; Boyett J
    Stat Med; 2007 Mar; 26(7):1497-511. PubMed ID: 16900551
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Bayesian approach for incorporating economic factors in sample size design for clinical trials of individual drugs and portfolios of drugs.
    Patel NR; Ankolekar S
    Stat Med; 2007 Nov; 26(27):4976-88. PubMed ID: 17579924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Consultants' forum: should post hoc sample size calculations be done?
    Walters SJ
    Pharm Stat; 2009; 8(2):163-9. PubMed ID: 18416448
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sample size estimation for non-inferiority trials of time-to-event data.
    Crisp A; Curtis P
    Pharm Stat; 2008; 7(4):236-44. PubMed ID: 17583558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design of phase II ALS clinical trials.
    Schoenfeld DA; Cudkowicz M
    Amyotroph Lateral Scler; 2008; 9(1):16-23. PubMed ID: 18273715
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blinded and seeing the light, (John Noseworthy), Lou Gehrig and other tales of enlightenment).
    Pascuzzi RM
    Semin Neurol; 1998; 18(3):415-8. PubMed ID: 9817544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. When was a "negative" clinical trial big enough? How many patients you needed depends on what you found.
    Detsky AS; Sackett DL
    Arch Intern Med; 1985 Apr; 145(4):709-12. PubMed ID: 3985731
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficient group sequential designs when there are several effect sizes under consideration.
    Jennison C; Turnbull BW
    Stat Med; 2006 Mar; 25(6):917-32. PubMed ID: 16220524
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparing the power of the discontinuation design to that of the classic randomized design on time-to-event endpoints.
    Capra WB
    Control Clin Trials; 2004 Apr; 25(2):168-77. PubMed ID: 15020035
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vasopressors and the search for the optimal trial design.
    Maharaj R
    Contemp Clin Trials; 2011 Nov; 32(6):924-30. PubMed ID: 21807122
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Robustness of an odds-ratio test in a stratified group sequential trial with a binary outcome measure.
    Srivastava DK; Rai SN; Pan J
    Biom J; 2007 Jun; 49(3):351-64. PubMed ID: 17623341
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent advances in the therapy of amyotrophic lateral sclerosis: focus on excitotoxicity.
    Brighina L; Sala G; Ceresa C; Tremolizzo L; Ferrarese C
    Funct Neurol; 2001; 16(4 Suppl):189-202. PubMed ID: 11996516
    [No Abstract]   [Full Text] [Related]  

  • 35. Confidence intervals for a ratio of two independent binomial proportions.
    Price RM; Bonett DG
    Stat Med; 2008 Nov; 27(26):5497-508. PubMed ID: 18781560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Conditional power calculations for clinical trials with historical controls.
    Korn EL; Freidlin B
    Stat Med; 2006 Sep; 25(17):2922-31. PubMed ID: 16479548
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Economics in sample size determination for clinical trials.
    Torgerson DJ; Ryan M; Ratcliffe J
    QJM; 1995 Jul; 88(7):517-21. PubMed ID: 7633878
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Group sequential clinical trials with triangular continuation regions.
    Whitehead J; Stratton I
    Biometrics; 1983 Mar; 39(1):227-36. PubMed ID: 6871351
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stopping clinical trials early for benefit: impact on estimation.
    Freidlin B; Korn EL
    Clin Trials; 2009 Apr; 6(2):119-25. PubMed ID: 19342463
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Sequential analysis in clinical and epidemiological research].
    van der Tweel I; Schipper M
    Ned Tijdschr Geneeskd; 2002 Dec; 146(49):2348-52. PubMed ID: 12510397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.